Outcome MeasureWell-being

WEMWBS

Warwick-Edinburgh Mental Wellbeing Scale

3 Papers in Blossom

Clinical Thresholds

Low

Average

High

1470

Low

Score 14–40

Average

Score 41–59

High

Score 60–70

Outcome Data Across Studies

Reported results for WEMWBS across 3 studies with quantitative data.

Outcome data across 5 study arm–timepoint observations
					SD
Trial of Psilocybin versus Escitalopram for Depression 2021Secondary	Psilocybin + placebo(experimental)	42	—	—Δ	—	—
Trial of Psilocybin versus Escitalopram for Depression 2021Secondary	Psilocybin + escitalopram(active_comparator)	42	—	—Δ	—	—
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression 2024Secondary	Psilocybin + placebo(experimental)	42	—	—Δ	—	—
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression 2024Secondary	Psilocybin + escitalopram(active_comparator)	42	—	—Δ	—	—
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up 2025Secondary	MDMA-assisted psychotherapy(experimental)	90	14	—Δ	—	—

Papers Using WEMWBS

Open Accessindividual

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up

In an open‑label feasibility study of 14 recently detoxified participants, Bayesian analysis estimated a 55–63% probability that MDMA‑assisted psychotherapy produced a two‑level reduction in WHO drinking‑risk at 3‑month follow‑up, with preliminary reductions in alcohol craving and improvements in sleep and psychosocial functioning. The paper frames a harm‑reduction endpoint for AUD and provides early evidence that MDMA‑assisted psychotherapy may improve quality of life alongside reduced drinking.

Published: June 9, 2025
Journal: Alcohol and Alcoholism
Authors: Thurgur, H., Sessa, B., Higbed, L., O'brien, S., Durant, C., Wilson, S., Szigeti, B., Morgan, C. J. A., Nutt, D. J.

Paywallindividual

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

In a double-blind randomised trial (n=55) comparing escitalopram and COMP360 psilocybin for major depressive disorder, pre-treatment expectancy predicted response to escitalopram but not to psilocybin, whereas baseline trait suggestibility was associated with response to psilocybin only. These findings suggest psychedelic therapy may be less vulnerable to expectancy biases but could be particularly effective in highly suggestible individuals.

Published: January 22, 2024
Journal: Psychological Medicine
Authors: Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L.

Open Accessindividual

Trial of Psilocybin versus Escitalopram for Depression

This double-blind placebo-controlled study (n=59) compared psilocybin (2x25mg; 3 weeks apart) to escitalopram (SSRI) over a six-week period and found large improvements in depression scores for those suffering from depression (MDD) in both groups. On the main measure of depression, the QIDS-SR-16, there was no significant difference between both groups. The study did find significant differences, favoring psilocybin, on the HAM-D-17, MADRS, avoidance, flourishing, wellbeing, and suicidality.

Published: April 15, 2021
Journal: New England Journal of Medicine
Authors: Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy, R., Murphy-Beiner, A., Martell, J., Blemings, A., Erritzoe, D., Nutt, D. J.

Quick Facts

Full Name: Warwick-Edinburgh Mental Wellbeing Scale
Domain: Well-being
Papers Indexed: 3
Score Range: 14–70
Interpretation: Higher = better

All Measures